Skip to main content


Clinician-Facing Decision Tool to Promote Access to Prostate Cancer Clinical Trials

February 20, 2021


Hala Borno, MD, University of California, San Francisco, discusses observations from a research study that evaluated the implementation of a clinician-facing decision tool to help promote access to clinical trials for patients with prostate cancer.

This study was presented at the virtual 2021 ASCO Genitourinary Cancers Symposium.

Follow Dr Borno on Twitter: @HalaBorno


Hi, my name is Dr. Hala Borno. I'm an assistant professor of medicine at the University of California San Francisco and a medical oncologist. I'm going to share with you a little bit about my observations from a research study deploying a clinician facing decision tool to help promote access to clinical trials.

At the University of California San Francisco, we developed a novel technology solution that includes all clinical trials that are available for patients with the prostate cancer diagnosis. This clinician decision tool was available online by going to

Clinicians were able to put in the attributes of the patients that they were evaluating for clinical trials and then generate a list of the clinical trials for which their patients may be eligible. That list also included the information of the research coordinator who was assigned that clinical trial and that other particularities of disease of the trial eligibility.

We found that this clinician-facing technology solution was very popular within our context, but it promoted transparency and a quick reference to identify clinical trials in real time for our patients. Not only that, there was also this novel opportunity.

When clinicians are able to populate the attributes of their patients onto a platform such as this, we can then generate a report that indicates all the different attributes for patients being considered for clinical trials. This report will give us the proportion of patients with oligometastatic disease, the proportion of patients with hormone‑sensitive disease vs hormone‑resistant disease and also characterize their prior treatment exposures.

All of these data are usually hard to come by but can inform investigator-initiated trial design and surface important feasibility data for guiding subsequent therapeutic trials that are selected for our patient population.

We are going to continue to deploy this decision tool within our clinical context. We are now expanding it to include other tumors and the clinical trials that are relevant to other urologic malignancies. Then, it will be a model that can be applied across the entire oncology sector and really change the ways in which we communicate trial availability within our health system.

Borno H, Li P, Zhang S. Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center. Presented at: the virtual 2021 ASCO Genitourinary Cancers Symposium; February 11-13, 2021. Abstract 19.   

Dr Borno reports no relevant financial relationships.

Back to Top